BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Rallybio’s Mission of Developing Transformative Medicines Heads Into the Clinic

  Since Rallybio launched in 2018, the company has been laser-focused on the development of “transformative therapeutics” for patients suffering from rare and ultra-rare diseases.

  January 13, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Policy

  Two Biotechs Duke it Out in Court Over COVID-19 Therapeutic

  NRx is seeking $185 million in damages and claims that Relief has breached the collaboration agreement established in 2020 regarding the development of the COVID-19 drug, aviptadil.

  January 13, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Adagio Makes Case for Anti-COVID-19 Antibody Based on New Data

  Adagio cited three recent independent, in vitro studies showing that ADG20, which is currently undergoing Phase II/III clinical trials, has neutralization activity against Omicron.

  January 13, 2022

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Drug Development

  COVID News: Diabetes Risk in Kids, AZ Booster, Protective Nasal Spray and More

  For a look at what’s going on with kids and COVID-19, and related stories, continue reading.

  January 13, 2022

   · 

  6 min read

   · 

  Mark Terry
• 

  Business

  Immunotherapy Shows Promise in Phase II on Tough T1D Path

  Imcyse’s peptides work by priming cytolytic T cells to recognize and destroy those immune cells attacking the pancreas beta cells.

  January 13, 2022

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Scorpion and AstraZeneca Strike $1.5B Deal Against Hard-to-Treat Proteins

  The companies believe the collaboration, valued at more than $1.5 billion, for up to three small molecule therapeutics has the potential to transform oncology treatments.

  January 13, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  BioMidwest

  Research Roundup: Genetically Modified Pig Heart Transplant and More

  One of the big stories this week that even momentarily eclipsed COVID-19, was the landmark transplant of a genetically modified pig heart into a human male with terminal heart disease. For that and more research stories, read on.

  January 13, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Denali’s Alzheimer’s Drug is on Hold but Company Expresses Positivity at JPM

  Denali Therapeutics announced that the FDA had placed a clinical hold on the IND application for DNL919 and would receive an official clinical hold letter from the agency in about 30 days.

  January 13, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Lysogene and Sarepta Part Ways on Gene Therapy for Rare Genetic Condition

  Lysogene and Sarepta Therapeutics will end a licensing agreement after failed discussions of transferring global commercial supply rights for the LYS-SAF302 asset back to Lysogene.

  January 13, 2022

   · 

  2 min read

   · 

  Alvin Clavines
• 

  Business

  BridgeBio and Amgen Unite on Combination Therapy for Advanced Solid Tumors

  BridgeBio Pharma had inked a non-exclusive clinical partnership with Amgen to study a combination of its BBP-398 with Amgen’s Lumakras in advanced solid tumors with the KRAS G12C mutation.

  January 13, 2022

   · 

  2 min read

   · 

  Mark Terry